Worldwide statins market worth $14B, with $25B potential in 2006, says MSDW
In 2000, the value of the worldwide statins market was $13.7 billion,with three products, Pfizer's Lipitor (atorvastatin), Merck & Co's Zocor (simvastatin) and Sankyo/Bristol-Myers Squibb's Pravachol (pravastatin), accounting for 89% of sales, according to analysts at Morgan Stanley Dean Witter.
The US market dominates the global landscape, accounting for 67% (or $9.2 billion) in 2000, up slightly from 65% in 1999. The analysts estimate that the worldwide market will grow at a compound annual growth rate of 11% over the next five years to reach a value of around $25.5 billion in 2006.
View market penetration of Crestor and Zocor/ezetimibe therapy
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze